297
Participants
Start Date
October 25, 2023
Primary Completion Date
July 30, 2027
Study Completion Date
December 31, 2028
TNFa Antagonist - Infliximab
• Infliximab 5 mg/kg intravenously \[IV\] at weeks 0, 2, 6, then 5 mg/kg every 8 weeks
TNFa Antagonist - Adalimumab
• Adalimumab subcutaneously \[SC\] 160 mg at week 0, 80 mg at week 2, then 40 mg every 2 weeks
Anti-IL12/23 or anti-IL23 - Ustekinumab
• Ustekinumab \~6 mg/kg IV x1, then 90 mg SC every 8 weeks
Anti-IL12/23 or anti-IL23 - Risankizumab
• Risankizumab 600 mg IV at weeks 0, 4, and 8, then 360 mg SC every 8 weeks
Anti-integrin - Vedolizumab IV
• Vedolizumab 300 mg IV at weeks 0, 2, and 6, then every 8 weeks
Anti-integrin - Vedolizumab IV and SC
• Vedolizumab 300 mg IV at weeks 0 and 2, then 108 mg SC every 2 weeks
RECRUITING
University of Calgary, Calgary
RECRUITING
University of Alberta IBD Clinic, Edmonton
NOT_YET_RECRUITING
GI Research Institute (G.I.R.I), Vancouver
NOT_YET_RECRUITING
West Coast Gastroenterology, Vancouver
ACTIVE_NOT_RECRUITING
Nova Scotia Health Victoria, Halifax
NOT_YET_RECRUITING
GNRR Digestive Clinics and Research Center Inc., Brampton
NOT_YET_RECRUITING
Rajbir Rai Medical Corporation, Brantford
RECRUITING
McMaster University, Hamilton
ACTIVE_NOT_RECRUITING
London Health Sciences Centre, London
NOT_YET_RECRUITING
West GTA Research Inc., Mississauga
NOT_YET_RECRUITING
ABP Research Services Corp., Oakville
NOT_YET_RECRUITING
Taunton Surgical Center, Oshawa
RECRUITING
The Ottawa Hospital Research Institute, Ottawa
ACTIVE_NOT_RECRUITING
Thunder Bay Regional Health Research Institute, Thunder Bay
RECRUITING
Mount Sinai Hospital, Toronto
ACTIVE_NOT_RECRUITING
TIDHI Clinic, Toronto
RECRUITING
Centre Hospitalier de l'Université de Montréal (CHUM), Montreal
RECRUITING
Hôpital du Sacré-Cœur-de-Montréal, Montreal
RECRUITING
Research Institute of the McGill University Health Centre (MUHC), Montreal
NOT_YET_RECRUITING
Université de Sherbrooke, Sherbrooke
Collaborators (1)
Alimentiv Inc.
OTHER
University of Calgary
OTHER